Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03744026
Other study ID # SC9-GBM-01
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date February 18, 2019
Est. completion date June 30, 2022

Study information

Verified date September 2022
Source CarThera
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Recurrent glioblastoma (GBM) is a disease with high unmet clinical need. The standard of care for patients with GBM includes surgery, radiotherapy and chemotherapy. Despite this aggressive treatment, the overall median survival of patients with GBM remains at 15-20 months. In more than 95% of cases, tumor recurrence is observed within 2 cm to 3 cm of the resection cavity within 4-7 months after initial treatments. One of the main causes of recurrence is the inability of chemotherapies to enter the brain from the systemic circulation due to the blood-brain barrier (BBB). The BBB is unique to cerebral blood vessels and blocks most drugs from entering the brain in sufficient concentrations. The SonoCloud-9 (SC9) System delivers ultrasound to locally and transiently increase the permeability of the BBB to allow the passage of drugs into the cerebral parenchyma. The SC9 is dimensioned to cover the resection area and surrounding tissues in patients with recurrent GBM. The large sonicated volume covered by the SC9 device allows for broad BBB disruption and should allow for carboplatin chemotherapy to penetrate the surrounding tumor infiltrative area. By enhancing drug concentrations, it is hypothesized that further disease progression will be prevented.


Description:

This will be an open-label, Phase 1/2a, multicenter, single-arm, interventional trial that will first evaluate the dose limiting toxicity (DLT) of escalating numbers of ultrasound beams at constant acoustic pressure using a standard escalation (Phase 1) and then confirm the safety and efficacy of BBB opening (Phase 2a expansion).


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date June 30, 2022
Est. primary completion date June 23, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Key Inclusion Criteria: 1. Age = 18 years, able and willing to give signed and informed consent. 2. Patient with histologically proven recurrent de novo GBM: 1. After at least a first-line standard of care (maximal safe resection, if feasible, radiation with temozolomide [TMZ], then TMZ); 2. Any recurrence; 3. Bevacizumab-naïve.* 3. Patient eligible for carboplatin-based chemotherapy. 4. Patient eligible for a surgical resection. 5. Maximal tumor diameter at inclusion (pre surgery) = 70 mm in T1wMRI. 6. Patients should be stable, without evidence of a midline shift, significant peritumoral edema, or rapid progression of clinical symptoms. 7. Karnofsky performance status = 70. 8. Patient receiving prednisone dose = 40 mg (dexamethasone = 6 mg) for at least 7 days. Key Exclusion Criteria: 1. Multifocal tumor (unless all localized in a 70 mm diameter area). 2. Patients at risk of surgery site infection (2 or more previous craniotomies, neurosurgery within the last 3 months, poor skin condition, and/or previously infected surgical field). 3. Posterior fossa tumor. 4. Uncontrolled epilepsy. 5. Patients with evidence of uncontrolled intracranial pressure. 6. Patients with known intracranial aneurism or having presented intra-tumor spontaneous hemorrhage. 7. Patients with coils, clips, shunts, intravascular stents, and/or unremovable wafer, non resorbable dura substitute, or reservoirs. 8. Patients with medical need to continue antiplatelet therapy. 9. Patients with known or suspected active or chronic infections.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
SonoCloud-9
Escalating numbers of ultrasound beams at constant acoustic pressure
Drug:
Carboplatin
Dose of carboplatin infusion is AUC4-6

Locations

Country Name City State
France CHU Angers
France Hôpital Neurologique Pierre Wertheimer Bron
France Hôpital de La Timone Marseille
France Hôpital de la Pitié-Salpêtrière Paris
United States Northwestern University Chicago Illinois
United States MD Anderson Cancer Center Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
CarThera

Countries where clinical trial is conducted

United States,  France, 

References & Publications (1)

Carpentier A, Canney M, Vignot A, Reina V, Beccaria K, Horodyckid C, Karachi C, Leclercq D, Lafon C, Chapelon JY, Capelle L, Cornu P, Sanson M, Hoang-Xuan K, Delattre JY, Idbaih A. Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Sci Transl Med. 2016 Jun 15;8(343):343re2. doi: 10.1126/scitranslmed.aaf6086. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Dose limiting toxicity (DLT) of number of activated ultrasound beams DLT will be evaluated using imaging (MRI) and clinical examination, as CTCAE that occurs within 2 weeks of the first sonication and that does not respond to optimal medical management (including steroids) within 7 days. 15 days after the first sonication treatment
Primary Blood-Brain Barrier (BBB) opening BBB opening will be evaluated by contrast-enhanced T1w magnetic resonance imaging (MRI) At the end of the first three sonication treatments (treatment occurs every 4 weeks)
See also
  Status Clinical Trial Phase
Completed NCT03291977 - Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME) Phase 3
Active, not recruiting NCT03665545 - Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma Phase 1/Phase 2
Terminated NCT03714334 - DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma Phase 1
Recruiting NCT03277638 - Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM) Phase 1/Phase 2
Completed NCT03158389 - NCT Neuro Master Match - N²M² (NOA-20) Phase 1/Phase 2
Completed NCT03522298 - Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma Phase 2
Recruiting NCT03213002 - Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM Phase 1/Phase 2
Completed NCT03232424 - NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma Phase 1
Active, not recruiting NCT04116658 - First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma Phase 1/Phase 2
Completed NCT03618667 - GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification Phase 2
Recruiting NCT04128774 - Function and Composition of Regulatory B Cells in Participants With Glioblastoma
Completed NCT04610229 - Safety of IMRT Treatment With Inhomogeneous Dose in Patients With Relapsed High-grade Gliomas. N/A
Active, not recruiting NCT02974738 - A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) Phase 1
Recruiting NCT03025893 - A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme Phase 2/Phase 3
Active, not recruiting NCT03181477 - Study Evaluating the Efficacy of Radiotherapy With SIB-IMRT, Associated With Temozolomide in Glioblastomas N/A
Completed NCT03075514 - Ketogenic Diets as an Adjuvant Therapy in Glioblastoma N/A

External Links